Great Ormond Street Hospital BRC

The NIHR Great Ormond Street Hospital (GOSH) Biomedical Research Centre (BRC) in partnership with the University College London (UCL) Great Ormond Street Institute of Child Health (GOS-ICH) is the leading children s medical research centre in Europe and the only BRC dedicated to children. At GOSH we see children with over 180 rare conditions.

Through the partnership between GOSH and GOS-ICH, and a new collaboration with children s hospitals in Birmingham, Sheffield and Liverpool, GOSH BRC s vision is to transform the health of children, and the adults they will become, by combining cutting edge research methods with world-leading clinical trial expertise, to accelerate discovery of new treatments for children with rare and complex conditions worldwide.

Involving these patients, their parents/carers and the public in the research process is essential to achieving our mission.

Since 2018, GOSH BRC research led to regulatory permissions being given for eleven new treatments for childhood rare conditions - 258 GOSH patients have now received these life-changing treatments.

We publish our work in international scientific journals, allowing our findings to be used by other hospitals to improve child health worldwide.

Since 2017 we raised £228 million of external financial support for research, representing a seven-fold return on current NIHR BRC investment.

GOSH implemented an electronic patient record system in 2019 and, in 2021, was the first UK hospital to be awarded HIMSS level 7 status (digital maturity measure), the highest possible rating.

ICH was awarded Athena-Swan GOLD in 2021, which recognises excellence in gender equality policies, and it also drives an active Race Equity programme.

UCL is among the top 10 universities worldwide in Medical Life Sciences and third in the UK for Medical and Biological Science.

Gene and cell therapies (GCT) are a particular strength, with GOSH and the UCL Hospital Trust providing 40% of the UK s GCTs.

The new Zayed Centre for Research into Rare Diseases in Children at GOSH houses seven production suites for GCT medicines, the largest UK academic facility.

Our five BRC Themes bring together the strengths of our partners and world-leading expertise from diverse researchers, with involvement of our unique patients, to focus on the follow areas.

GENE STEM and CELLULAR THERAPIES builds on our world-leading expertise to develop new therapies for childhood cancer and immunological, blood, brain, skin and metabolic conditions.

GENOMIC MEDICINE uses cutting-edge technology and new ways of analysing large data-sets to improve diagnosis and help develop treatments.

ACCELERATING NOVEL THERAPIES supports bringing new medicines into clinical practice by delivering clinical trials and stem-cell based evaluation of therapies.

TISSUE ENGINEERING and REGENERATIVE MEDICINE develops pioneering laboratory and surgical techniques to repair, replace or regenerate tissues or organs.

APPLIED CHILD HEALTH INFORMATICS uses advanced data analysis methods, leveraging GOSH s electronic patient data, to improve management of children with rare and/or complex conditions.

Alongside our themes, the BRC CENTRAL DEVELOPMENTAL HUB supports our highly successful Career Development Academy, commercial and public involvement activities, which are vital to our continued efforts to translate research into patient benefits.